Loading
Coaching-based weight loss did not clearly cut breast cancer recurrence in BWEL, perhaps because the weight loss was too small. Drugs that produce three times as much weight loss could settle whether weight itself matters.
BWEL achieved modest weight loss with no clear iDFS effect. Bariatric surgery cohorts, with 25-30% weight loss, show large reductions in hormone-related cancers. GLP-1 receptor agonists sit between the two and are already widely used by breast cancer survivors off-trial; a randomised trial would answer the biological question BWEL could not and define safety alongside endocrine therapy (lean mass loss, bone density, gastrointestinal effects with CDK4/6 inhibitors).
Shares Energy balance, Body composition (lean mass, fat mass, visceral fat), Dietitian-led weight-loss programmes in HR-positive breast cancer, GLP-1 receptor agonists and obesity-related cancer risk.
Shares BWEL (Breast Cancer Weight Loss, Alliance A011401), Dietitian-led weight-loss programmes in HR-positive breast cancer.
Shares Letrozole (and other aromatase inhibitors), Abemaciclib, Eli Lilly (incl. Loxo), HR-positive / HER2-negative breast cancer.
Shares Energy balance, Dietitian-led weight-loss programmes in HR-positive breast cancer, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs).
Shares Energy balance, GLP-1 receptor agonists and obesity-related cancer risk, Obesity-related cancers (IARC list of 13).
Shares A trial of GLP-1 weight-loss drugs with cancer as the primary outcome, GLP-1 receptor agonists and obesity-related cancer risk, Obesity-related cancers (IARC list of 13).
Shares Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.